Department of Ophthalmology, Duke Eye Center, Duke University School of Medicine, Durham, NC, USA.
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Ocul Surf. 2022 Jul;25:40-48. doi: 10.1016/j.jtos.2022.04.007. Epub 2022 Apr 27.
To investigate the efficacy and safety of plasma rich in growth factors (PRGF) eyedrops in the management of patients with ocular surface diseases in North America.
Multicenter interventional case series of patients using PRGF eyedrops for the first time. A cohort of patients was analyzed for corneal staining score at initial visit and at 3 months of therapy with PRGF. Another cohort responded to a 10-item questionnaire that evaluated patients' satisfaction and safety, which included the symptom assessment questionnaire in dry eye (SANDE) score, after 6 months of PRGF treatment.
A total of 153 patients were analyzed. Of these, 102 were reviewed for corneal epitheliopathy and 99 patients responded to the questionnaire. The mean (±SD) age of the population was 63.7 ± 17 years and 72.5% were female. The clinical indications for PRGF usage were dry eye (60%), neurotrophic keratopathy (15%), dormant corneal ulcers (12%), limbal stem cell deficiency (10%), and cicatrizing conjunctivitis (4%). At the final visit, 74.3% of patients showed an improvement of their corneal staining. Those who had punctate epithelial erosions or epithelial defects were reduced from 76.5% to 47% and 23.5% to 7.8% respectively (p < 0.0001). Symptoms, measured via SANDE score, significantly decreased from a median of 90 to 34.6 out of 100 points on follow-up (p < 0.0001). Only one patient (0.98%) complained of ocular burning sensation as a side effect.
This multicentric study demonstrates the safety and efficacy of the use of PRGF for treating signs and symptoms in patients with significant ocular surface diseases.
研究富含生长因子的血浆（PRGF）滴眼液在北美的眼表疾病患者管理中的疗效和安全性。
首次使用 PRGF 滴眼液的多中心介入性病例系列研究。对一组患者的角膜染色评分进行分析，在初始就诊时和使用 PRGF 治疗 3 个月时进行分析。另一组患者在使用 PRGF 治疗 6 个月后，通过一项评估患者满意度和安全性的 10 项问卷进行了回复，其中包括干眼症状评估问卷（SANDE）评分。
共分析了 153 例患者，其中 102 例回顾了角膜上皮病，99 例患者回复了问卷。该人群的平均（±标准差）年龄为 63.7±17 岁，72.5%为女性。PRGF 使用的临床指征包括干眼（60%）、神经营养性角膜病变（15%）、休眠性角膜溃疡（12%）、角膜缘干细胞缺乏症（10%）和瘢痕性结膜炎（4%）。在最后一次就诊时，74.3%的患者角膜染色得到改善。点状上皮糜烂或上皮缺损患者分别从 76.5%降至 47%和 23.5%降至 7.8%（p<0.0001）。通过 SANDE 评分测量的症状从中位数 90 分显著降低至随访时的 34.6 分（p<0.0001）。只有 1 例患者（0.98%）抱怨眼部烧灼感作为副作用。
这项多中心研究表明，PRGF 用于治疗有明显眼表疾病患者的体征和症状是安全有效的。
